NASDAQ:KPRX Kiora Pharmaceuticals (KPRX) Stock Price, News & Analysis $3.31 -0.11 (-3.22%) (As of 11/21/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Kiora Pharmaceuticals Stock (NASDAQ:KPRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Kiora Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.31▼$3.4150-Day Range$3.10▼$4.0452-Week Range$3.00▼$8.98Volume2,973 shsAverage Volume72,551 shsMarket Capitalization$9.93 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingStrong Buy Company OverviewKiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.Read More… What Comes Next Could Be a Once-in-a-Lifetime Opportunity (Ad)A wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come.Click here now to watch the full briefing and discover the steps to take today. Kiora Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks60th Percentile Overall ScoreKPRX MarketRank™: Kiora Pharmaceuticals scored higher than 60% of companies evaluated by MarketBeat, and ranked 451st out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingKiora Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageKiora Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Kiora Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Kiora Pharmaceuticals are expected to decrease in the coming year, from $0.89 to ($2.48) per share.Price to Book Value per Share RatioKiora Pharmaceuticals has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Kiora Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.76% of the float of Kiora Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverKiora Pharmaceuticals has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kiora Pharmaceuticals has recently increased by 1,197.22%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKiora Pharmaceuticals does not currently pay a dividend.Dividend GrowthKiora Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.76% of the float of Kiora Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverKiora Pharmaceuticals has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kiora Pharmaceuticals has recently increased by 1,197.22%, indicating that investor sentiment is decreasing significantly. News and Social Media0.9 / 5News Sentiment-0.44 News SentimentKiora Pharmaceuticals has a news sentiment score of -0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Kiora Pharmaceuticals this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for KPRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Kiora Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,800.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 0.94% of the stock of Kiora Pharmaceuticals is held by insiders.Percentage Held by Institutions76.97% of the stock of Kiora Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kiora Pharmaceuticals' insider trading history. Receive KPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kiora Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address KPRX Stock News HeadlinesEquities Analysts Issue Forecasts for KPRX FY2024 EarningsNovember 16, 2024 | americanbankingnews.comWe Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be ConservativeNovember 15, 2024 | finance.yahoo.comWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come.November 22, 2024 | InvestorPlace (Ad)Kiora Pharmaceuticals’ Promising Growth Prospects: Buy Rating Backed by Clinical Advancements and Strong Financial PositionNovember 13, 2024 | markets.businessinsider.comPositive Developments and Strategic Partnerships Propel Kiora Pharmaceuticals to a Buy RatingNovember 1, 2024 | markets.businessinsider.comKiora Pharmaceuticals Gains Approval for Phase 2 TrialOctober 29, 2024 | markets.businessinsider.comKiora Pharmaceuticals (NASDAQ:KPRX) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comBuy Rating on Kiora Pharmaceuticals Amid Promising Clinical Trials and Strong FinancialsAugust 23, 2024 | markets.businessinsider.comSee More Headlines KPRX Stock Analysis - Frequently Asked Questions How have KPRX shares performed this year? Kiora Pharmaceuticals' stock was trading at $4.7016 at the beginning of 2024. Since then, KPRX stock has decreased by 29.6% and is now trading at $3.31. View the best growth stocks for 2024 here. How were Kiora Pharmaceuticals' earnings last quarter? Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) posted its quarterly earnings results on Friday, November, 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.90) by $0.09. When did Kiora Pharmaceuticals' stock split? Kiora Pharmaceuticals's stock reverse split on Tuesday, June 11th 2024. The 1-9 reverse split was announced on Tuesday, June 11th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 11th 2024. An investor that had 100 shares of stock prior to the reverse split would have 11 shares after the split. How do I buy shares of Kiora Pharmaceuticals? Shares of KPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Kiora Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kiora Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Jabil (JBL) and CrowdStrike (CRWD). Company Calendar Last Earnings11/08/2024Today11/21/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/24/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KPRX CUSIPN/A CIK1372514 Webeyegatepharma.com Phone(781) 788-9043FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+202.1%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,510,000.00 Net MarginsN/A Pretax Margin35.21% Return on Equity21.32% Return on Assets16.39% Debt Debt-to-Equity RatioN/A Current Ratio8.97 Quick Ratio8.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.01 per share Price / Book0.33Miscellaneous Outstanding Shares3,000,000Free Float2,973,000Market Cap$9.93 million OptionableNot Optionable Beta-0.29 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NASDAQ:KPRX) was last updated on 11/22/2024 by MarketBeat.com Staff From Our PartnersTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredCentral Bank Abandons USDYou know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our...Desko Digital | SponsoredWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who unde...InvestorPlace | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of...Golden Crest | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiora Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiora Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.